Ligand Pharmaceuticals Incorporated Common Stock (LGND)
Stock · NASDAQ · Health Care
$295.53as of 10/16/2026
Price chart
Active signals
LGND Signal Track Record
How signals performed across all stocks →What LGND's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 29 | +4.9% | 66% | September 18, 2026 |
| Bollinger Band Breakout | 25 | +2.9% | 56% | September 22, 2026 |
| Bollinger Band Breakdown | 18 | +7.0% | 78% | September 15, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -5.0% | 43% | June 9, 2025 |
| Any 20-session window (baseline) | +2.5% | 60% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococca…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 47
- Website
- www.ligand.com/
Fundamentals
- 1-day range
- $292.64$297.67
- Market cap
- $6.02B
- P/E (trailing)
- 30.38
- P/E (forward)
- 24.73
- EPS (trailing)
- $9.40
- Dividend yield
- —
- Beta
- 1.24
- Avg. volume
- 251.6K
- Ex-dividend date
- July 2, 2010
How Ligand Pharmaceuticals Incorporated Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Ligand Pharmaceuticals Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- LGNDLigand Pharmaceuticals Incorporated Common Stock$295.54▼ 0.99%Market cap $6.02BP/E 30.38$175.89$326.63
- KNSAKiniksa Pharmaceuticals International plc Class A Ordinary Shares$78.59▼ 1.69%Market cap $5.97BP/E 77.33$35.2$82.94
- PTCTPTC Therapeutics Inc. Common Stock$59.24▼ 2.87%Market cap $5.91BP/E —$58.8$90.87
- TVTXTravere Therapeutics Inc. Common Stock$49.6▼ 6.04%Market cap $5.89BP/E —$22.59$68.73
- DNTHDianthus Therapeutics Inc. Common Stock$72.09▼ 3.27%Market cap $6.15BP/E —$32.22$117.88
- XENEXenon Pharmaceuticals Inc. Common Shares$33.49▼ 2.45%Market cap $6.24BP/E —$33.52$72.66
- ERASErasca Inc. Common Stock$13.39▼ 9.95%Market cap $6.25BP/E —$2.11$24.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals Incorporated Common Stock | $6.02B | 30.38 | $295.54 | ▼ 0.99% | $175.89$326.63 |
| KNSA Kiniksa Pharmaceuticals International plc Class A Ordinary Shares | $5.97B | 77.33 | $78.59 | ▼ 1.69% | $35.2$82.94 |
| PTCT PTC Therapeutics Inc. Common Stock | $5.91B | — | $59.24 | ▼ 2.87% | $58.8$90.87 |
| TVTX Travere Therapeutics Inc. Common Stock | $5.89B | — | $49.6 | ▼ 6.04% | $22.59$68.73 |
| DNTH Dianthus Therapeutics Inc. Common Stock | $6.15B | — | $72.09 | ▼ 3.27% | $32.22$117.88 |
| XENE Xenon Pharmaceuticals Inc. Common Shares | $6.24B | — | $33.49 | ▼ 2.45% | $33.52$72.66 |
| ERAS Erasca Inc. Common Stock | $6.25B | — | $13.39 | ▼ 9.95% | $2.11$24.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Here's How Much $1000 Invested In Ligand Pharmaceuticals 15 Years Ago Would Be Worth Todaybenzinga · 10/13/2026
- Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings CallBenzinga · 10/7/2026
- Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?Yahoo · 9/29/2026
- Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty DealYahoo · 9/29/2026
- Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?Yahoo · 9/29/2026
- Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup CautionChartMill · 9/28/2026
- Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to MilestonesYahoo · 9/27/2026
- IBM upgrade, SpaceX initiation among today's top calls on Wall StreetYahoo · 9/25/2026
- Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345Benzinga · 9/25/2026
Insider Activity
Insider Actions →- Reardon Andrew · October 2, 2026 · Option Exercise340 @ $52.27
- Reardon Andrew · October 2, 2026 · Sale17 @ $307.74
- Reardon Andrew · October 2, 2026 · Sale235 @ $307.19
- Reardon Andrew · October 2, 2026 · Sale404 @ $306.18
- Reardon Andrew · October 2, 2026 · Sale1.5K @ $304.52
- Reardon Andrew · October 2, 2026 · Sale2.0K @ $303.54
- Reardon Andrew · October 2, 2026 · Sale833 @ $302.51
- Zimmermann Martine · September 22, 2026 · Tax Withholding115 @ $298.5
- Zimmermann Martine · September 10, 2026 · Sale1.2K @ $285
- Reardon Andrew · September 3, 2026 · Sale385 @ $287.53
- Reardon Andrew · September 3, 2026 · Sale400 @ $288.98
- Reardon Andrew · September 3, 2026 · Sale2.1K @ $286.36
- Reardon Andrew · September 3, 2026 · Sale1.8K @ $285.17
- Reardon Andrew · September 3, 2026 · Sale300 @ $283.99
- Espinoza Octavio · August 12, 2026 · Option Exercise2.1K @ $70.04
Institutional Ownership
March 31, 2026
- Total shares held
- 19.50M
- Total value held
- $3.81B
- Institutional holders
- 346
- Unknown2.96M
- Unknown1.01M
- Unknown848.1K
- Unknown823.6K
- Unknown778.9K
- Unknown596.1K
- Unknown573.3K
- Unknown573.2K
- Unknown561.7K
- Unknown558.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript
Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.
Ligand Pharmaceuticals Releases Q2 2026 Earnings Call Transcript. Ligand Pharmaceuticals has published the full transcript of its second-quarter 2026 earnings call, providing investors with detailed management commentary on recent performance. While the stock currently trades near a key support level, the release of this transcript offers a deeper look into the company's operational updates and strategic outlook beyond the headline financial figures.